证券代码：600196 股票简称：复星医药 编号：临 2025-102 新任职工董事简历请见附件。 特此公告。 上海复星医药（集团）股份有限公司 董事会 二零二五年六月六日 1 附件：新任职工董事简历 严佳女士，1980 年 9 月生，现任本公司联席首席财务官、总裁助理、总会 计师、创新药事业部首席财务官，并于本公司若干控股子公司担任董事、监事职 务。严佳女士于 2002 年 9 月至 2008 年 12 月曾任安永会计师事务所审计经理； 于 2009 年 3 月首次加入本集团（即本公司及控股子公司/单位，下同），于 2009 年 3 月至 2017 年 5 月期间历任本公司财务审计副总监、财务审计总监、财务部 副总经理兼会计总监；于 2017 年 6 月至 2019 年 4 月任上海复星高科技（集团） 有限公司（以下简称"复星高科技"）母婴与家庭产业集团副总裁兼首席财务官, 于 2019 年 5 月至 2020 年 3 月任百合佳缘网络集团股份有限公司（已于 2019 年 12 月从新三板摘牌，原股票代码：834214）董事、首席财务官兼董事会秘书， 于 2020 年 4 月至 2020 年 7 月任复星高 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-101 上海复星医药（集团）股份有限公司 关于修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 鉴于上海复星医药（集团）股份有限公司（以下简称"本公司"或"公司"） 已完成《上海复星医药（集团）股份有限公司 2022 年限制性 A 股股票激励计划》 （以下简称"本次激励计划"）项下共计 897,140 股 A 股限制性股票的回购及注 销，本公司的注册资本、总股本发生相应变化，根据《中华人民共和国公司法》 以及本公司 2022 年第二次临时股东大会、2022 年第二次 A 股类别股东会及 2022 年第二次 H 股类别股东会（以下合称"股东会"）的授权，经本公司第九届董事 会第八十一次会议审议通过，同意对《上海复星医药（集团）股份有限公司章程》 (以下简称"《公司章程》")作如下修订： 上海复星医药（集团）股份有限公司 董事会 二零二五年六月六日 2 1 | 修订前 | | | | | | | | | | | | 修订后 | | | | | | | ...

证券代码：600196 股票简称：复星医药 编号：临 2025-100 上海复星医药（集团）股份有限公司 第九届董事会第八十一次会议（临时会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"或"公司"）第九 届董事会第八十一次会议（临时会议）于2025年6月6日召开，全体董事以通讯方式 出席了会议，本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司 法》"）、其他有关法律法规和《上海复星医药（集团）股份有限公司章程》（以 下简称"《公司章程》"）的规定。会议审议并达成如下决议： 审议通过关于修订《公司章程》的议案。 现修订为："公司于 2012 年 4 月 5 日经中国证监会 2012[444]号文件核准发 行境外上市外资股（H 股），并获得香港联交所批准，公司 H 股股份于 2012 年 10 月 30 日于香港联交所挂牌上市。 公司的股本结构为：内资股贰拾壹亿壹仟捌佰肆拾捌万捌仟捌佰贰拾伍 (2,118,488,825)股；境外上市外资股伍亿伍仟壹佰 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 表格類別： | 股票 狀態： 新提交 | | --- | --- | | 公司名稱： | 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) | | 呈交日期： | 2025年6月6日 | 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | ...

Summary of Key Points from Conference Call Records Industry or Company Involved 1. **Innovative Pharmaceuticals**: Focus on the pharmaceutical sector with a specific mention of Fosun Pharma and its recent drug approvals [1][5][6] 2. **Livestock Farming**: Highlighting the pig farming industry with a focus on Juxing Agriculture [10][14] 3. **Artificial Turf**: Discussing the artificial turf industry with a focus on Gongchuang Turf [15][18] Core Points and Arguments Innovative Pharmaceuticals 1. **R&D Investment**: In 2024, the company maintained stable R&D intensity with total R&D investment of 5.554 billion yuan, of which 4.910 billion yuan was allocated to pharmaceutical business, representing 16.98% of pharmaceutical revenue [1][8] 2. **Product Approval**: The company received approval for its new drug, Luwo Meitini tablets, for treating rare tumors, addressing unmet medical needs [5][6] 3. **Revenue Growth**: The pharmaceutical segment is expected to achieve revenue of 28.924 billion yuan in 2024, with a profit of 3.250 billion yuan, reflecting a year-on-year growth of 65.73% [7][8] 4. **International Expansion**: The company is advancing its internationalization strategy, with several drugs receiving approvals in the US and Europe [9] Livestock Farming 1. **Production Goals**: Juxing Agriculture aims to achieve a pig output of over 4 million heads in 2025, with a current capacity of over 180,000 breeding pigs [10][14] 2. **Market Conditions**: The industry is benefiting from lower feed costs and improved disease control, enhancing resilience against market fluctuations [10][13] 3. **Performance Metrics**: In 2024, the company reported a pig output of 2.7552 million heads, with a 50.76% year-on-year increase in commercial pig output [14] Artificial Turf 1. **Market Growth**: The global artificial turf market is projected to grow from 22.063 billion yuan in 2023 to 38.2 billion yuan by 2030, driven by the advantages of artificial turf over natural grass [15] 2. **Revenue Breakdown**: In 2024, the company achieved domestic revenue of 319 million yuan and international revenue of 2.616 billion yuan, with respective year-on-year growth rates of 12.5% and 21.0% [18] 3. **Production Capacity**: The company has a total production capacity of 116 million square meters, with significant expansions planned in Vietnam and Mexico [19] Other Important but Possibly Overlooked Content 1. **Healthcare Services**: The healthcare services segment reported a revenue increase of 14.61% in 2024, although it still faced losses due to ongoing investments in specialized services and smart healthcare [8] 2. **Cash Flow Stability**: Juxing Agriculture reported a positive operating cash flow of 0.059 billion yuan in Q1 2025, indicating stable operational efficiency [20] 3. **Cost Management**: Gongchuang Turf demonstrated effective cost control with a decrease in expense ratios, contributing to improved profitability [19] This summary encapsulates the essential insights from the conference call records, highlighting the performance and strategic directions of the companies involved in the innovative pharmaceuticals, livestock farming, and artificial turf industries.

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

FF301 本月底法定/註冊股本總額： RMB 2,670,429,325 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年6月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 2. 股份分類 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 回購股份的進展公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 2025 年6 月3 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：600196 证券简称：复星医药 公告编号：2025-0 ...

证券代码：600196 证券简称：复星医药 公告编号：2025-099 上海复星医药（集团）股份有限公司 关于回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） 截至 2025 年 5 月 31 日，回购进展如下： | | A 股回购方案 | H 股回购方案 | | --- | --- | --- | | 回购方案 | 2025/1/23 | 2025/1/23 | | 首次披露日 | | | | 回购方案 | 2025/1/22~2025/7/21 | 2025/1/22~2025/7/21 | | 实施期限 | | | | （含首尾两日） | | | | 预计回购金额 | 人民币30,000万元~60,000万元 | 不适用 | | | □减少注册资本 | 包括但不限于注销或作为库存 | | | √用于员工持股计划或股权激励 | 股份等 | | 回购用途 | √用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | | （上述二者之一或二者皆有） | | | ...

Group 1 - The Shanghai Composite Index opened lower but rose throughout the day, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7971.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 5.53% in the past month, 7.39% in the past three months, and 7.09% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.29%), WuXi AppTec (16.43%), Pian Zai Huang (6.37%), Yunnan Baiyao (5.21%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (4.06%), Xinhecheng (3.51%), Changchun High-tech (3.48%), Fosun Pharma (3.34%), and Shanghai Raas (3.27%) [1] - The market segments of the CSI 300 Pharmaceutical and Biotechnology Index show that the Shanghai Stock Exchange accounts for 63.65% and the Shenzhen Stock Exchange accounts for 36.35% [2] - The industry composition of the CSI 300 Pharmaceutical and Biotechnology Index includes: chemical drugs (43.80%), pharmaceutical and biotechnology services (21.66%), traditional Chinese medicine (18.52%), and biological drugs (16.02%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index samples [2]